Zion Market Research has published a new report titled "Cancer Biomarkers Market by Biomarker Type (Genetic Biomarkers, Protein Biomarkers, and Other Biomarkers); by Cancer Type (Breast Cancer, Colorectal Cancer, Lung Cancer, Prostate Cancer, Blood Cancer, Melanoma, Ovarian Cancer, Liver Cancer, Stomach Cancer, and Other Cancer Types); by Profiling Technology (Imaging technologies, Omic Technologies (Proteomics, Genomics, and Other Omic Technologies), Cytogenetics-Based Tests, and Immunoassays); and for Application (Drug Discovery and Development, Personalized medicine, Diagnostics, and Other Applications): Global Industry Perspective, Comprehensive Analysis and Forecast, 2018 - 2024". According to the report, global cancer biomarkers market was valued at approximately USD 11,000 million in 2017 and is expected to generate revenue of around USD 26,000 million by end of 2024, growing at a CAGR of around 13% between 2018 and 2024.